Amy Pierce

899 total citations
21 papers, 557 citations indexed

About

Amy Pierce is a scholar working on Infectious Diseases, Virology and Gastroenterology. According to data from OpenAlex, Amy Pierce has authored 21 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 10 papers in Virology and 3 papers in Gastroenterology. Recurrent topics in Amy Pierce's work include HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (10 papers) and HIV/AIDS Research and Interventions (9 papers). Amy Pierce is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), HIV Research and Treatment (10 papers) and HIV/AIDS Research and Interventions (9 papers). Amy Pierce collaborates with scholars based in United States, United Kingdom and Brazil. Amy Pierce's co-authors include Jerry Snidow, Eric Mortensen, C. Kleoudis, John I. Wurzelmann, Ben Lasko, Gordon Irving, Eric Carter, Bart Morlion, Lynn R. Webster and John F. Peppin and has published in prestigious journals such as New England Journal of Medicine, Pain and Ophthalmology.

In The Last Decade

Amy Pierce

21 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Pierce United States 11 168 167 137 120 79 21 557
Xia Qiu China 13 101 0.6× 40 0.2× 76 0.6× 4 0.0× 10 0.1× 36 520
Sowsan Rasheid United States 5 164 1.0× 14 0.1× 22 0.2× 25 0.2× 11 0.1× 9 353
Min Min China 14 117 0.7× 58 0.3× 73 0.5× 25 0.2× 2 0.0× 40 494
Eleonora Albano Italy 10 103 0.6× 44 0.3× 24 0.2× 2 0.0× 7 0.1× 12 459
Parnian Jamshidi Iran 11 42 0.3× 22 0.1× 206 1.5× 21 0.2× 14 0.2× 16 449
Xuan Jiang China 9 107 0.6× 89 0.5× 105 0.8× 1 0.0× 164 2.1× 25 554
Marina Khoury Argentina 10 25 0.1× 20 0.1× 7 0.1× 5 0.0× 20 0.3× 45 389
Sangam Shah Nepal 10 53 0.3× 3 0.0× 66 0.5× 24 0.2× 10 0.1× 109 375
Saurabh Gupta Australia 11 318 1.9× 63 0.4× 47 0.3× 62 0.5× 10 0.1× 41 499
Mario Sánchez Borges Venezuela 12 119 0.7× 5 0.0× 96 0.7× 4 0.0× 17 0.2× 19 1.0k

Countries citing papers authored by Amy Pierce

Since Specialization
Citations

This map shows the geographic impact of Amy Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Pierce more than expected).

Fields of papers citing papers by Amy Pierce

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Pierce. The network helps show where Amy Pierce may publish in the future.

Co-authorship network of co-authors of Amy Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Pierce. A scholar is included among the top collaborators of Amy Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Pierce. Amy Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thakkar, Nilay, Rulan Griesel, Amy Pierce, et al.. (2025). Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV. Infectious Diseases and Therapy. 14(6). 1313–1326. 2 indexed citations
2.
Thakkar, Nilay, Rulan Griesel, Amy Pierce, et al.. (2025). Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV. Infectious Diseases and Therapy. 14(5). 1011–1025. 2 indexed citations
3.
Llibre, Josep M., Judith A. Aberg, Sharon Walmsley, et al.. (2024). Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study. Frontiers in Immunology. 15. 1394644–1394644. 1 indexed citations
4.
Clark, Andrew, et al.. (2024). Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study. Open Forum Infectious Diseases. 11(9). ofae469–ofae469. 1 indexed citations
5.
Aberg, Judith A., Christine Katlama, Shannon Schrader, et al.. (2023). Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1. Infectious Diseases and Therapy. 12(9). 2321–2335. 7 indexed citations
6.
Seibert, Susan A., et al.. (2023). Preferred resiliency-building strategies of nursing students. Teaching and learning in nursing. 18(4). e200–e204. 4 indexed citations
7.
Gartland, Margaret, Pedro Cahn, Edwin DeJesus, et al.. (2022). Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. Antimicrobial Agents and Chemotherapy. 66(6). e0175121–e0175121. 10 indexed citations
8.
Pierce, Amy, et al.. (2021). Developing Cultural Humility Among Prelicensure Nursing Students. Nurse Educator. 47(1). 46–46. 1 indexed citations
9.
Anderson, Sarah‐Jane, Miranda Murray, David Cella, et al.. (2021). Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals. Patient. 15(1). 131–143. 2 indexed citations
10.
Ginzler, Ellen M., David D’Cruz, Richard Furie, et al.. (2021). Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 74(1). 112–123. 72 indexed citations
11.
Wit, Stéphane De, et al.. (2021). 834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial. Open Forum Infectious Diseases. 8(Supplement_1). S509–S509. 1 indexed citations
12.
Ackerman, Peter, Melanie Thompson, Jean‐Michel Molina, et al.. (2021). Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 35(7). 1061–1072. 13 indexed citations
13.
Gartland, Margaret, Nannan Zhou, Eugene L. Stewart, et al.. (2020). Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay. Journal of Antimicrobial Chemotherapy. 76(3). 648–652. 11 indexed citations
14.
Miller, Michael D., Judith A. Aberg, Gilles Pialoux, et al.. (2020). Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. New England Journal of Medicine. 382(13). 1232–1243. 102 indexed citations
15.
Johnstone, Patti M., et al.. (2017). Using Microphone Technology to Improve Speech Perception in Noise in Children with Cochlear Implants. Journal of the American Academy of Audiology. 29(9). 814–825. 14 indexed citations
16.
Csaky, Karl G., Pravin U. Dugel, Amy Pierce, et al.. (2014). Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. Ophthalmology. 122(3). 579–588. 59 indexed citations
17.
Jansen, Jan‐Peter, Daniel Lorch, Ben Lasko, et al.. (2011). A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain. Journal of Pain. 12(2). 185–193. 59 indexed citations
18.
Irving, Gordon, Brian Ramjattan, Michael J. Cousins, et al.. (2011). A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain. Journal of Pain. 12(2). 175–184. 59 indexed citations
19.
20.
Pierce, Amy, et al.. (1991). TESTER INDEPENDENT SUPPORT SOFTWARE SYSTEM (TISSS). Defense Technical Information Center (DTIC). 685–691. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xia Qiu Breakdown of academic impact, for papers by Sowsan Rasheid Breakdown of academic impact, for papers by Min Min Breakdown of academic impact, for papers by Eleonora Albano Breakdown of academic impact, for papers by Parnian Jamshidi Breakdown of academic impact, for papers by Xuan Jiang Breakdown of academic impact, for papers by Marina Khoury Breakdown of academic impact, for papers by Sangam Shah Breakdown of academic impact, for papers by Saurabh Gupta Breakdown of academic impact, for papers by Mario Sánchez Borges
Rankless by CCL
2026